CR20140305A - Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de transtornos inflamatorios - Google Patents

Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de transtornos inflamatorios

Info

Publication number
CR20140305A
CR20140305A CR20140305A CR20140305A CR20140305A CR 20140305 A CR20140305 A CR 20140305A CR 20140305 A CR20140305 A CR 20140305A CR 20140305 A CR20140305 A CR 20140305A CR 20140305 A CR20140305 A CR 20140305A
Authority
CR
Costa Rica
Prior art keywords
novedose
dihydropirimidinoisoquinolinones
treatment
same
pharmaceutical compositions
Prior art date
Application number
CR20140305A
Other languages
English (en)
Spanish (es)
Inventor
Frédéric Gilbert Labéguère
Gregory John Robert Newsome
Luke Jonathan Alvey
Laurent Raymond Maurice Sanière
Stephen Robert Fletcher
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of CR20140305A publication Critical patent/CR20140305A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CR20140305A 2011-12-22 2014-06-24 Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de transtornos inflamatorios CR20140305A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161578979P 2011-12-22 2011-12-22

Publications (1)

Publication Number Publication Date
CR20140305A true CR20140305A (es) 2014-07-23

Family

ID=47520068

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140305A CR20140305A (es) 2011-12-22 2014-06-24 Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de transtornos inflamatorios

Country Status (34)

Country Link
US (5) US8927543B2 (enExample)
EP (3) EP2794604B1 (enExample)
JP (1) JP6062453B2 (enExample)
KR (1) KR102012268B1 (enExample)
CN (1) CN103998448B (enExample)
AR (1) AR089284A1 (enExample)
AU (1) AU2012357067B2 (enExample)
BR (1) BR112014015142B1 (enExample)
CA (1) CA2859578C (enExample)
CL (1) CL2014001664A1 (enExample)
CO (1) CO7010835A2 (enExample)
CR (1) CR20140305A (enExample)
CY (2) CY1119434T1 (enExample)
DK (2) DK3378862T3 (enExample)
EA (1) EA023826B1 (enExample)
ES (2) ES2911449T3 (enExample)
HR (2) HRP20171404T1 (enExample)
HU (1) HUE12812237T4 (enExample)
IL (2) IL233212B (enExample)
IN (1) IN2014MN01033A (enExample)
LT (2) LT3378862T (enExample)
MX (1) MX351681B (enExample)
NI (1) NI201400060A (enExample)
PE (1) PE20141685A1 (enExample)
PH (1) PH12014501178B1 (enExample)
PL (2) PL3378862T3 (enExample)
PT (2) PT3378862T (enExample)
SG (1) SG11201403169PA (enExample)
SI (2) SI3378862T1 (enExample)
TW (1) TWI567073B (enExample)
UA (1) UA111767C2 (enExample)
UY (1) UY34545A (enExample)
WO (1) WO2013092791A1 (enExample)
ZA (1) ZA201404607B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356509B (es) 2011-12-22 2018-05-30 Alios Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9708312B2 (en) * 2012-12-20 2017-07-18 Galapagos Nv Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists)
GB201319677D0 (en) * 2013-11-07 2013-12-25 Eth Z Rich Cyclopropanation
GB201411241D0 (en) * 2014-06-25 2014-08-06 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201506894D0 (en) 2015-04-23 2015-06-10 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CN108530480B (zh) * 2017-03-06 2022-06-28 中国科学院上海药物研究所 Gpr84受体拮抗剂及其应用
EP3403649A1 (en) 2017-05-16 2018-11-21 Bayer Pharma Aktiengesellschaft Inhibitors and antagonists of gpr84 for the treatment of endometriosis
AU2018367193A1 (en) * 2017-11-15 2020-07-02 Galapagos Nv Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
EP4077334B1 (en) 2019-12-19 2025-03-12 Bayer Aktiengesellschaft Furoindazole derivatives
WO2021123394A1 (en) 2019-12-20 2021-06-24 University Of Copenhagen G protein-coupled receptor modulators and a pharmaceutical composition
EP4251160A1 (en) 2020-11-24 2023-10-04 Galapagos N.V. Compound for use in and methods of treatment of fibrotic diseases
US12378229B2 (en) 2021-02-02 2025-08-05 Liminal Biosciences Limited GPR84 antagonists and uses thereof
EP4298102A1 (en) 2021-02-23 2024-01-03 Bayer Aktiengesellschaft Furoindazole derivatives as gpr84 antagonists
WO2022194267A1 (zh) * 2021-03-18 2022-09-22 武汉人福创新药物研发中心有限公司 一种gpr84拮抗剂及其制备方法和用途
WO2022218372A1 (zh) * 2021-04-14 2022-10-20 武汉人福创新药物研发中心有限公司 一种二氢嘧啶并异喹啉酮类衍生物及用途
US20240239804A1 (en) 2021-04-29 2024-07-18 Bayer Aktiengesellschaft Furoindazole derivatives as antagonists or inhibitors of gpr84
WO2022263676A1 (en) 2021-06-18 2022-12-22 University Of Copenhagen Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
CN115572293A (zh) * 2021-06-21 2023-01-06 武汉人福创新药物研发中心有限公司 用于gpr84拮抗剂的三环化合物
CN115611944A (zh) 2021-07-15 2023-01-17 中国科学院上海药物研究所 不对称gpr84拮抗剂及其用途
WO2023076668A1 (en) * 2021-10-29 2023-05-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for treatment of cancer
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
WO2024083705A1 (en) 2022-10-18 2024-04-25 Bayer Aktiengesellschaft Furoindazole derivatives for the treatment of pain
CN120569392A (zh) * 2022-12-30 2025-08-29 广州市联瑞制药有限公司 三环类化合物及其制备方法和应用
WO2024220480A2 (en) * 2023-04-17 2024-10-24 The Board Of Trustees Of The Leland Stanford Junior University Method for detecting innate immune action in vivo using gpr84-pet
TW202506117A (zh) 2023-06-26 2025-02-16 英商維羅納製藥Plc公司 顆粒組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2720085A1 (de) 1977-05-05 1978-11-16 Hoechst Ag Pyrimido(6,1-a)isochinolin-2-on- derivate
WO1999002162A1 (en) * 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibiting purine derivatives
JP2002543046A (ja) * 1999-03-31 2002-12-17 バーナリス・リミテッド ピリミド[6,1−a]イソキノリン−4−オン誘導体
EP1641766A2 (en) * 2003-07-08 2006-04-05 Smithkline Beecham Corporation Novel chemical compounds
WO2005050225A2 (en) 2003-10-31 2005-06-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2007027661A2 (en) * 2005-09-02 2007-03-08 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
EP2318377B1 (en) 2008-07-31 2013-08-21 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
JP2011088847A (ja) * 2009-10-21 2011-05-06 Takeda Chem Ind Ltd 三環性化合物およびその用途
MX358696B (es) 2011-12-22 2018-08-31 Connexios Life Sciences Pvt Ltd Derivados de aza adamantano y lo usos de los mismos.
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
DK2794600T3 (en) 2011-12-22 2018-03-12 Novartis Ag -2,3-Dihydro-benzo [1,4] oxazine derivatives and related compounds such as phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of rheumatoid arthritis
WO2013128465A1 (en) 2011-12-22 2013-09-06 Connexios Life Sciences Pvt. Ltd. Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof
US9708312B2 (en) 2012-12-20 2017-07-18 Galapagos Nv Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists)

Also Published As

Publication number Publication date
EA201491245A1 (ru) 2014-10-30
PH12014501178A1 (en) 2014-10-20
LT2794604T (lt) 2017-10-25
AU2012357067B2 (en) 2017-01-05
PH12014501178B1 (en) 2014-10-20
PT3378862T (pt) 2022-04-11
PL2794604T3 (pl) 2017-12-29
PL3378862T3 (pl) 2022-05-16
CO7010835A2 (es) 2014-07-31
IL233212B (en) 2018-03-29
ES2643379T3 (es) 2017-11-22
DK2794604T3 (da) 2017-11-06
US20220227751A1 (en) 2022-07-21
BR112014015142A2 (pt) 2017-06-13
IL257581A (en) 2018-04-30
KR102012268B1 (ko) 2019-08-21
UA111767C2 (uk) 2016-06-10
EP2794604A1 (en) 2014-10-29
EP3378862B1 (en) 2022-03-16
KR20140117427A (ko) 2014-10-07
EP4019519A1 (en) 2022-06-29
HRP20171404T1 (hr) 2017-11-17
IL233212A0 (en) 2014-08-31
US20190002458A1 (en) 2019-01-03
HK1201528A1 (en) 2015-09-04
HRP20220456T1 (hr) 2022-05-27
EP2794604B1 (en) 2017-09-13
AU2012357067A1 (en) 2014-07-10
CL2014001664A1 (es) 2014-10-03
PE20141685A1 (es) 2014-11-25
PT2794604T (pt) 2017-10-23
US20140121204A1 (en) 2014-05-01
TW201331201A (zh) 2013-08-01
MX2014007363A (es) 2014-08-01
US20160244442A1 (en) 2016-08-25
CN103998448B (zh) 2016-04-20
ZA201404607B (en) 2020-02-26
EP3378862A1 (en) 2018-09-26
HUE12812237T4 (hu) 2017-12-28
US8927543B2 (en) 2015-01-06
MX351681B (es) 2017-10-25
SI3378862T1 (sl) 2022-05-31
JP6062453B2 (ja) 2017-01-18
ES2911449T3 (es) 2022-05-19
EA023826B1 (ru) 2016-07-29
CA2859578A1 (en) 2013-06-27
NI201400060A (es) 2015-04-27
US11220499B2 (en) 2022-01-11
WO2013092791A1 (en) 2013-06-27
US20130165437A1 (en) 2013-06-27
SG11201403169PA (en) 2014-07-30
JP2015500861A (ja) 2015-01-08
CY1119434T1 (el) 2018-03-07
LT3378862T (lt) 2022-04-25
NZ626473A (en) 2016-03-31
ES2643379T9 (es) 2018-01-05
SI2794604T1 (sl) 2017-12-29
US9255095B2 (en) 2016-02-09
CY1125167T1 (el) 2024-09-20
CA2859578C (en) 2020-03-10
TWI567073B (zh) 2017-01-21
BR112014015142B1 (pt) 2022-03-29
CN103998448A (zh) 2014-08-20
AR089284A1 (es) 2014-08-13
DK3378862T3 (da) 2022-04-11
IN2014MN01033A (enExample) 2015-05-01
US10047083B2 (en) 2018-08-14
UY34545A (es) 2013-07-31

Similar Documents

Publication Publication Date Title
CR20140305A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de transtornos inflamatorios
JOP20180103A1 (ar) مركب صيدلاني
CR20140312A (es) 4-fenil-piridinas sustiuidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
MX377552B (es) Proceso para preparar un compuesto antiviral de formula i.
CR20140042A (es) Indazoles
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
UY35700A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
CR20140301A (es) Derivados de betulina
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
MX2013012760A (es) Nuevos compuestos y composiciones para la inhibicion de nampt.
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
CR20140510A (es) Nucleósidos de espirooxetano de uracilo
ECSP13013074A (es) Nuevos derivados de piridina
UY33735A (es) Compuestos antivirales
CR20130369A (es) Novedosos derivados heterocíclicos
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
EA201490037A1 (ru) Антагонисты trpv4
CU20140055A7 (es) Procedimiento de preparación de 5- fluoro- 1h-pirazolopiridinas sustituidas
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
IN2013MN02014A (enExample)
CR20140094A (es) Derivados de etinilo
EA201391371A1 (ru) Фармацевтическая композиция ситаглиптина
CR20130501A (es) Derivados novedosos de cefalosporinas y composiciones farmacéuticas de estos
MX2014003169A (es) Ligandos del receptor ep1.
CR20140322A (es) Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2